Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. RYTELO demonstrated strong commercial momentum, with net product revenue growing substantially as the company expanded its U.S. commercial efforts and clinical development programs. Geron is also advancing the Phase 3 IMpactMF trial to explore potential label expansion in myelofibrosis, alongside investigator-sponsored and real-world evidence studies. The company pursues a focused strategy on hematology-oncology, leveraging telomerase inhibition as a mechanism to address blood cancers. Founded in 1990 and headquartered in Foster City, California, Geron operates as a single-segment organization dedicated to bringing innovative therapeutic options to patients with serious blood disorders and malignancies.